Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients

被引：2

作者：

Aarnoutse, RE ^{[1
]}

Brinkman, K

Benetucci, J

Begovac, J

Stek, M

Burger, DM

机构：

[1] Univ Med Ctr Geneva, Dept Clin Pharm, Nijmegen, Netherlands

[2] Onze Lieve Vrouw Hosp, Dept Internal Med, Amsterdam, Netherlands

[3] FUNDAI, Hosp Infect Dis, Dept Infectiol, Francisco J Muniz Hosp, Buenos Aires, DF, Argentina

[4] Univ Zagreb, Univ Hosp Infect Dis Dr Fran Mihaljevic, HR-10002 Zagreb, Croatia

[5] Merck & Co Inc, Whitehouse Stn, NJ USA

来源：

AIDS | 2004年 / 18卷 / 03期

关键词：

D O I：

10.1097/00002030-200402200-00026

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A pharmacokinetic study was performed in HIV-infected patients who used indinavir/ritonavir (800/100 mg twice a day) plus efavirenz in the European and South American Study of Indinavir, Efavirenz and Ritonavir. Indinavir plasma concentrations were similar to values previously obtained in healthy volunteers who used the same combination. Efavirenz concentrations were higher than reported before. The pharmacokinetic data suggest that indinavir/ritonavir plus efavirenz (without dose modifications) should be effective in treatment-naive patients, and this was supported by the treatment response of the participants.

引用

页码：565 / 567

页数：3

共 7 条

[1] The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers [J].

Aarnoutse, RE ;

Grintjes, KJT ;

Telgt, DSC ;

Stek, M ;

Hugen, PWH ;

Reiss, P ;

Koopmans, PP ;

Hekster, YA ;

Burger, DM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) :57-67

[2] Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: A randomized, double-blind, placebo-controlled trial [J].

Haas, DW ;

Fessel, WJ ;

Delapenha, RA ;

Kessler, H ;

Seekins, D ;

Kaplan, M ;

Ruiz, NM ;

Ploughman, LM ;

Labriola, DF ;

Manion, DJ .

JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (03) :392-400

[3] Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography [J].

Hugen, PWH ;

Verweij-van Wissen, CPWGM ;

Burger, DM ;

Wuis, EW ;

Koopmans, PP ;

Hekster, YA .

JOURNAL OF CHROMATOGRAPHY B, 1999, 727 (1-2) :139-149

[4] Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].

Marzolini, C ;

Telenti, A ;

Decosterd, LA ;

Greub, G ;

Biollaz, J ;

Buclin, T .

AIDS, 2001, 15 (01) :71-75

[5] Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults [J].

Staszewski, S ;

Morales-Ramirez, J ;

Tashima, KT ;

Rachlis, A ;

Skiest, D ;

Stanford, J ;

Stryker, R ;

Johnson, P ;

Labriola, DF ;

Farina, D ;

Manion, DJ ;

Ruiz, NM .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) :1865-1873

[6]

STEK M, 2002, 14 INT AIDS C BARC S

[7]

1996, PRODUCT MONOGRAPH CR

← 1 →